Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients. Weight loss was similar in both groups: -2.8+/-3.2 kg vs. -1.4+/-2.6 kg. Except for preventing a triglyceride increase, the drug combination lacked efficacy for metabolic control in this clinical population.
Baptista
Trino
T
Department of Physiology, Los Andes University Medical School, P.O. Box 93, Mérida, 5101-A, Venezuela. trinbap@yahoo.com
Uzcátegui
Euderruh
E
Rangel
Nairy
N
El Fakih
Yamily
Y
Galeazzi
Tatiana
T
Beaulieu
Serge
S
de Baptista
Enma Araujo
EA
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001067:Appetite Depressants / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D002908:Chronic Disease; D003503:Cyclobutanes / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000188:drug therapy*; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced* / Q000188:drug therapy*; D000077152:Olanzapine; D010865:Pilot Projects; D010919:Placebos; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D049629:Waist-Hip Ratio; D015430:Weight Gain / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
D014150:Antipsychotic Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D007004:Hypoglycemic Agents; D010919:Placebos; D001569:Benzodiazepines; D008687:Metformin; D000077152:Olanzapine; C058254:sibutramine